In the second arm, the team compared more than 32,000 GLP-1 patients against more than 96,000 patients taking SGLT-2 inhibitors between 2013 and 2020
This article describes GLP-1 peptide characteristics and the mechanisms mediating its known role in increasing insulin, decreasing glucagon, delaying gastric emptying, and promoting satiety
Michael Law, a pharmaceutical policy researcher and academic director of the Centre for Health Policy at the University of Calgary, said this type of product launch is unusual but would give Novo Nordisk new ways of competing for market share when generics come on the market
With India being the diabetes capital of the world, the entry of a globally trusted GLP-1 therapy brings: Better glycaemic control Proven cardiovascular benefits Once-weekly dosing convenience A new benchmark in patient-centric diabetes care This launch is not just about a drug its about reshaping treatment outcomes, improving adherence, and elevating quality of life for millions of patients
Youll receive a confirmation email with tracking information once your order has shipped
doi: 10.7759/cureus.27335, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 46.Lingvay I, Cohen RV, le Roux CW, Sumithran P